$RNAZ

Transcode Therapeutics, Inc.

TransCode Therapeutics is a clinical-stage biotechnology company developing immuno-oncology and RNA therapeutics for people with high-risk and advanced cancers. Its lead candidate, TTX-MC138, is an antisense inhibitor of microRNA-10b, and the company’s TTX platform is designed to deliver RNA and other therapeutic payloads to tumors and metastatic sites. Its other RNA programs include TTX-siPDL1, TTX-RIGA and TTX-siMYC. TransCode also develops Seviprotimut-L, a polyvalent antigen vaccine for patients with stage IIB and IIC melanoma, through its acquisition of Polynoma. Under a license from Unleash Immuno Oncolytics, it holds rights to UIO-524, UIO-525 and UIO-526, an oncolytic immunotherapy platform involving genetically engineered adenoviruses. TransCode is headquartered in Boston, Massachusetts.

No enriched coverage for $RNAZ in the last 7 days.

No SEC Form 4 filings for $RNAZ in the last 30 days.

See all $RNAZ insider activity →
Low

TransCode Advances Colorectal Cancer Drug to Phase 2

TransCode Therapeutics, a public biotech company, announced its lead drug TTXMC138 for colorectal cancer has advanced to Phase 2 trials. The drug targets microRNA-10b, a key regulator in metastatic cancer. Phase 1 results showed safety and some efficacy, with 71% of patients experiencing stable disease. The company has raised $100M with no long-term debt. Phase 2 trials focus on colorectal cancer, a high-mortality disease with unmet medical needs.

TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio

Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio Lead program TTX-MC138 is in Phase 2a clinical development for ctDNA-positive colorectal cancer following curative-int

An experimental cancer treatment could be licensed or sold as TransCode weighs options

TransCode Therapeutics is exploring strategic options for its lead cancer treatment, TTX-MC138, which is in Phase 2a trials for colorectal cancer. The company has engaged Tungsten Advisors to evaluate potential transactions, including licensing or selling assets. TTX-MC138 is designed to inhibit miR-10b, and preliminary data showed stable disease in some patients. TransCode aims to maximize value for shareholders through this process.

RNAZ sentiment & insider activity

Recent RNAZ coverage spans financial news, corporate actions and technology.

What's driving RNAZ

  • TransCode Therapeutics, a public biotech company, announced its lead drug TTXMC138 for colorectal cancer has advanced to Phase 2 trials. The drug targets microRNA-10b, a key regulator in metastatic cancer. Phase 1 results showed safety and some efficacy, with 71% of patients experiencing stable disease. The company has raised $100M with no long-term debt. Phase 2 trials focus on colorectal cancer, a high-mortality disease with unmet medical needs.

    bioxconomy.com · Nov 16, 2026

  • The announcement introduces uncertainty about future financing and potential dilution, likely weighing on the stock.

    SEC EDGAR 8-K · Oct 28, 2026

  • TransCode Therapeutics is exploring strategic options for its lead cancer treatment, TTX-MC138, which is in Phase 2a trials for colorectal cancer. The company has engaged Tungsten Advisors to evaluate potential transactions, including licensing or selling assets. TTX-MC138 is designed to inhibit miR-10b, and preliminary data showed stable disease in some patients. TransCode aims to maximize value for shareholders through this process.

    stocktitan.net · Oct 28, 2026

  • Positive safety data may lift the stock as investors anticipate further development.

    investing.com · Oct 26, 2026

  • The announcement may generate modest buying interest as investors anticipate data, but no concrete results are provided yet.

    prnewswire.com · Oct 19, 2026

AlphAI scores every news story that mentions RNAZ with an AI model for sentiment and relevance, and aggregates insider trades from Transcode Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RNAZ

Score

TransCode Advances Colorectal Cancer Drug to Phase 2

TransCode Therapeutics, a public biotech company, announced its lead drug TTXMC138 for colorectal cancer has advanced to Phase 2 trials. The drug targets microRNA-10b, a key regulator in metastatic cancer. Phase 1 results showed safety and some efficacy, with 71% of patients experiencing stable disease. The company has raised $100M with no long-term debt. Phase 2 trials focus on colorectal cancer, a high-mortality disease with unmet medical needs.

$RNAZLowM&A· announced

TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio

Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio Lead program TTX-MC138 is in Phase 2a clinical development for ctDNA-positive colorectal cancer following curative-int

An experimental cancer treatment could be licensed or sold as TransCode weighs options

TransCode Therapeutics is exploring strategic options for its lead cancer treatment, TTX-MC138, which is in Phase 2a trials for colorectal cancer. The company has engaged Tungsten Advisors to evaluate potential transactions, including licensing or selling assets. TTX-MC138 is designed to inhibit miR-10b, and preliminary data showed stable disease in some patients. TransCode aims to maximize value for shareholders through this process.

$RNAZMedAI 8/10

TransCode presents phase 1a trial data for cancer therapy

TransCode Therapeutics (RNAZ) presented Phase 1a trial data for TTX-MC138 at ESMO Congress 2026. The study met safety endpoints, showed dose-dependent exposure, and indicated disease stabilization and extended progression-free intervals in some patients. TTX-MC138 is being evaluated in a Phase 2a trial under the PRE-I-SPY program.

TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026

TransCode Therapeutics (RNAZ) will present Phase 1a clinical trial data for TTX-MC138, its lead therapeutic candidate, at ESMO Congress 2026. The poster highlights the evaluation of TTX-MC138 in patients with advanced solid tumors, targeting miR-10b, a microRNA linked to metastatic disease progression. The presentation is scheduled for October 23, 2026, in Madrid, Spain.

Transcode Therapeutics, Inc. (RNAZ): Entry into a Material Definitive Agreement

Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement As previously disclosed by TransCode Therapeutics, Inc. (the “Company”) in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2026, the Company entered into a Standby Equity P

$RNAZMedAI 8/10Clinical / regulatory· topline data

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors · I

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

TransCode Therapeutics (RNAZ) announced patent advancements in Australia and Japan for its RNA-based cancer therapy platform. The Australian patent covers siRNA delivery for cancer treatment, while the Japanese patent focuses on RNA-based immunomodulation. These developments strengthen the company's global IP portfolio and support its lead therapeutic candidate, TTX-MC138.

$RNAZLowExec change· resigned

Transcode Therapeutics, Inc. (RNAZ): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Director On September 1

Related tickers